Sihuan Pharmaceutical Holdings Group Ltd. (the “Company,” stock code: 0460) has announced the repurchase of 15,000,000 shares in the open market on October 17, 2025, under a general mandate granted at the annual general meeting held on June 6, 2025. The shares were bought at an average price of HK$1.4505 each, amounting to approximately HK$21,757,500 in total or around 0.1636% of the Company’s issued shares (excluding treasury shares).

Sihuan Pharmaceutical intends to hold the repurchased shares as treasury shares for potential subsequent sale or transfer. According to the announcement, the management believes that this move aligns with the interests of both the Company and its shareholders. Recent business developments include notable progress in medical aesthetics and innovative pharmaceuticals. Revenue from the Company’s medical aesthetic segment reached approximately RMB585 million for the six months ended June 30, 2025, reflecting an approximate 81% year-on-year increase. As of September 30, 2025, 15 new medical aesthetic products and drugs have been approved for market launch, including three self-developed Class III medical device products and 12 additional drugs, boosting confidence in the Company’s future growth.

Founded in 2001 and listed on the Main Board of the Stock Exchange in 2010, Sihuan Pharmaceutical operates as an international medical aesthetics and biopharmaceutical group. Its strategic focus centers on advancing medical aesthetics and biopharmaceutical businesses, supported by research and development capabilities, efficient production platforms, and established sales networks. The share repurchase remains subject to market conditions at the discretion of the board of directors, and no guarantee is given regarding the timing, amount, or price of further repurchases.